Your browser doesn't support javascript.
The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells.
Tomita, Yuriko; Takeda, Makoto; Matsuyama, Shutoku.
  • Tomita Y; Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
  • Takeda M; Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
  • Matsuyama S; Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan matuyama@nih.go.jp.
Antimicrob Agents Chemother ; 2021 Mar 01.
Article in English | MEDLINE | ID: covidwho-2284291
ABSTRACT
Favipiravir (T-705, commercial name Avigan), a drug developed to treat influenza virus infection, has been used in some countries as an oral treatment for COVID-19; however, its clinical efficacy in this context is controversial.….

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: AAC.00020-21

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: AAC.00020-21